Stephen E Spurgeon
Overview
Explore the profile of Stephen E Spurgeon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
2840
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gopal A, Armand P, Neelapu S, Bartlett N, Spurgeon S, Kuruvilla J, et al.
Blood Adv
. 2025 Mar;
PMID: 40030000
Despite high response rates, anti-PD-1 therapy monotherapy eventually fails in most patients with relapsed or refractory Hodgkin Lymphoma (HL) and is generally ineffective in most other B-cell malignancies. The lymphocyte...
2.
Shouse G, Chen L, Siddiqi T, Muir A, Brown J, Spurgeon S, et al.
Leuk Lymphoma
. 2024 Jun;
65(10):1516-1519.
PMID: 38836342
No abstract available.
3.
Wang M, Barrientos J, Furman R, Mei M, Barr P, Choi M, et al.
NEJM Evid
. 2024 Feb;
1(1):EVIDoa2100001.
PMID: 38319241
BACKGROUND: Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is an oncofetal protein present on many cancers. Zilovertamab vedotin (ZV) is an antibody–drug conjugate comprising a monoclonal antibody recognizing extracellular ROR1,...
4.
Banerjee T, Newman M, Chen A, Maziarz R, Schachter L, Spurgeon S, et al.
Leuk Lymphoma
. 2023 Jun;
64(8):1472-1475.
PMID: 37287113
No abstract available.
5.
Agrawal P, David K, Chen Z, Sundaram S, Kim S, Vaca R, et al.
Leuk Lymphoma
. 2023 Mar;
64(5):1026-1034.
PMID: 36960939
The objective of this multicenter retrospective study was to examine the incidence, patient characteristics, pathology, and outcomes associated with Epstein-Barr virus (EBV)-related CNS lymphoma (CNSL) in older patients. Among 309...
6.
Ujjani C, Gooley T, Spurgeon S, Stephens D, Lai C, Broome C, et al.
Blood Adv
. 2022 Dec;
7(17):4728-4737.
PMID: 36516082
Previous studies have demonstrated low rates of seroconversion to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA (mRNA) vaccines in patients with chronic lymphocytic leukemia (CLL). In this national...
7.
LeBlanc F, Hasanali Z, Stuart A, Shimko S, Sharma K, Leshchenko V, et al.
Oncotarget
. 2022 Sep;
13:986-1002.
PMID: 36093297
Classical MCL (cMCL) constitutes 6-8% of all B cell NHL. Despite recent advances, MCL is incurable except with allogeneic stem cell transplant. Blastic mantle cell lymphoma (bMCL) is a rarer...
8.
Bottomly D, Long N, Schultz A, Kurtz S, Tognon C, Johnson K, et al.
Cancer Cell
. 2022 Jul;
40(8):850-864.e9.
PMID: 35868306
Acute myeloid leukemia (AML) is a cancer of myeloid-lineage cells with limited therapeutic options. We previously combined ex vivo drug sensitivity with genomic, transcriptomic, and clinical annotations for a large...
9.
Wang M, Jurczak W, Jerkeman M, Trotman J, Zinzani P, Belada D, et al.
N Engl J Med
. 2022 Jun;
386(26):2482-2494.
PMID: 35657079
Background: Ibrutinib, a Bruton's tyrosine kinase inhibitor, may have clinical benefit when administered in combination with bendamustine and rituximab and followed by rituximab maintenance therapy in older patients with untreated...
10.
Chopra P, Andeen N, Spurgeon S
Kidney360
. 2022 Apr;
2(5):916-917.
PMID: 35373070
No abstract available.